You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,829,158


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,829,158
Title:Peptides, derivatives and analogs thereof, and methods of using same
Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
Inventor(s): Levetan; Claresa S. (Rosemont, PA), Upham; Loraine V. (Albuquerque, NM)
Assignee: CureDM Group Holdings, LLC (Wilmington, DE)
Application Number:13/745,706
Patent Claims:1. A method of treating pre-diabetes, type 1 diabetes, type 2 diabetes, latent autoimmune diabetes, or hyperglycemia in a subject in need thereof comprising: administering to the subject a therapeutically effective amount of a daily dose of a pharmaceutical composition comprising a human proislet peptide consisting of the amino acid sequence selected from SEQ ID No. 3, SEQ ID No: 7 and a combination thereof, wherein the daily dose is from 1 mg/kg to 100 mg/kg.

2. The method of claim 1 further comprising the step of administering one or more agents for stimulating pancreatic islet cell regeneration.

3. The method of claim 2, wherein the agent for stimulating pancreatic islet cell regeneration is selected from a member of the group consisting of human proislet peptide, amylin, pramlinitide, exendin-4, liraglutide, GLP-1 receptor agonists, GLP-1, hamster INGAP, GIP, dipeptydyl peptidase-4 inhibitors and analogs thereof.

4. The method of claim 1 further comprising the step of administering one or more agents that inhibit autoimmune cells that target pancreatic islet cells.

5. The method of claim 4, wherein the agent that inhibits the autoimmune cells that target pancreatic islet cells is selected from the group consisting of anti-antibody , rapamycin, FK506, heat-shock protein, tacrolimus, GAD65 vaccine, mycophenolate mofetil, lysofylline, rituximab, daclizumab, anti-CD52 antibody, anti-CD20 antibody, Vitamin D, IBC-VSO vaccine, interferon alpha and CD4.sup.+CD25.sup.+antigen-specific regulatory T cells.

6. The method of claim 5, wherein the vitamin D is vitamin D3.

7. The method of claim 6, wherein the vitamin D3 is administered to the subject in an amount effective to maintain 25-hydroxy vitamin D above about 40 ng/mL in the subject.

8. The method of claim 1, wherein the subject is a mammal.

9. The method of claim 8, wherein the mammal is selected from a human, a horse, a cow, a sheep, a dog and a cat.

10. The method of claim 1, wherein the peptide is SEQ ID No. 3.

11. The method of claim 1, wherein the peptide is SEQ ID No. 7.

12. The method of claim 1, wherein the peptide is administered in a pharmaceutical composition.

13. The method of claim 1, wherein the peptide is administered to said subject by a route selected from orally, subcutaneously, transdermally, intranasally, parenterally, topically and buccally.

14. The method of claim 1 further comprising administering insulin.

15. The method of claim 1, wherein said human proislet peptide is conjugated to a compound selected from albumin, transferrin and polyethylene glycol.

Details for Patent 8,829,158

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2025-05-25
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2025-05-25
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 12/10/1997 ⤷  Try a Trial 2025-05-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.